CN107157943A - A kind of Topiroxostat preparation and preparation method thereof - Google Patents
A kind of Topiroxostat preparation and preparation method thereof Download PDFInfo
- Publication number
- CN107157943A CN107157943A CN201710351488.6A CN201710351488A CN107157943A CN 107157943 A CN107157943 A CN 107157943A CN 201710351488 A CN201710351488 A CN 201710351488A CN 107157943 A CN107157943 A CN 107157943A
- Authority
- CN
- China
- Prior art keywords
- topiroxostat
- dripping pill
- inclusion compound
- inclusion
- stabilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UBVZQGOVTLIHLH-UHFFFAOYSA-N 4-[5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl]-pyridine-2-carbonitrile Chemical compound C1=NC(C#N)=CC(C=2N=C(NN=2)C=2C=CN=CC=2)=C1 UBVZQGOVTLIHLH-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229950004176 topiroxostat Drugs 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 239000006187 pill Substances 0.000 claims abstract description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 239000011159 matrix material Substances 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 13
- 239000003381 stabilizer Substances 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 229960003511 macrogol Drugs 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical group [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 6
- 102100033220 Xanthine oxidase Human genes 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940116269 uric acid Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 4
- 229960003459 allopurinol Drugs 0.000 description 4
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Topiroxostat preparation and preparation method thereof, Topiroxostat preparation of the invention is pill, is made up of Topiroxostat inclusion compound, matrix and stabilizer, and the inclusion compound includes Topiroxostat and inclusion material.Dripping pill roundness of the present invention is good, and drug-eluting is rapid, and bioavilability is high, simple production process, products obtained therefrom steady quality, is adapted to large-scale production.
Description
Technical field
The present invention relates to a kind of Western medicine preparation technology, more particularly to a kind of Topiroxostat dripping pill, the invention further relates to the drop
The preparation method of ball, belongs to pharmaceutical technology field.
Background technology
Hyperuricemia refers to serum uric acid value more than 7.0mg/dL, is uric acid mineralization disease（Urarthritis, kidney are damaged
Wound etc.）Etiological, show as serum uric acid concentration more than the solubility in body fluid.Gout is with serum uric acid level liter
Height, the Monosodium urate microscopic grains of hypersaturated state are separated out, and are deposited on the tissues such as joint, synovial membrane, tendon, kidney and connective tissue or device
Official, forms gout calculus, triggers Acute and chronic inflammation and tissue damage, the multisystems such as arthritis, lithangiuria and kidney diaseases occurs
Infringement.China there are about gout, the people of Patients with Hyperuricemia 1.2 hundred million, and Gao Fa Nian Ling is middle-aging male and postmenopausal women, but closely
There is rejuvenation trend over year.The anti-trioxypurine medicine used existing at present has the shortcomings that different degrees of, still needs to be improved.
Topiroxostat is the selective xanthine oxidase of no purine formation（XOR）Inhibitor.To oxidized form and reduced form
XOR have a significant inhibitory action, thus its reduce uric acid effect it is more powerful, lasting, therefore Topiroxostat can be used for controlling
Treat gout, hyperuricemia.There are two clear superiorities compared with allopurinol：1st, allopurinol only has suppression to the XOR of reduced form
Make and use, and Topiroxostat has significant inhibitory action to the XOR of oxidized form and reduced form, thus it reduces the effect of uric acid
It is more powerful, lasting；2nd, because allopurinol is purine analogue, inevitably cause to be related to purine and pyridine is metabolized other enzymes
The influence of activity, therefore, it is necessary to repeat heavy dose of administration to maintain higher levels of drugs in allopurinol treatment, thus also band
Carry out the serious or even fatal adverse reaction caused by drug accumulation, and Topiroxostat is non-purines XOR inhibitor, therefore
With more preferable security.
Dripping pill is simple using equipment, and process conditions are easily controllable；The quality of the pharmaceutical preparations is stable, accurate measurement；Matrix accommodates liquid
Medication amount is big, can solidify liquid drug；The dripping pill prepared with solid dispersion technology, which has, absorbs rapid, bioavilability height.
Inclusion compound has advantages below：Bad stink is covered, medicine irritation, increase drug dissolution and bioavilability is reduced, and
Improve medicine stability.
The content of the invention
Poor in order to solve existing Topiroxostat preparation stability, the low shortcoming of bioavilability researches and develops a kind of steady quality
Dripping pill, the present invention by lot of experiments to auxiliary material screen and process optimization there is provided a kind of Topiroxostat dripping pill.First will support department
He is prepared into inclusion compound, and dripping pill is then prepared into again, and inclusion is united two into one with dripping pill technology, plays both sides advantage.Should
Dripping pill steady quality, bioavilability is high.
To achieve the above object, the present invention is adopted the technical scheme that：
A kind of Topiroxostat dripping pill, including Topiroxostat, inclusion material, matrix, stabilizer, condensate liquid, it is characterised in that by weight
Percentage note is measured, each component content is：
Topiroxostat 5-15%
Include material 10-20%
Matrix 70-80%
Stabilizer 1%
Appropriate condensate liquid
Preferably, remember by weight percentage, each component content is：
Topiroxostat 10%
Include material 15%
Matrix 75%
Stabilizer 1%
Appropriate condensate liquid
Wherein, the inclusion material is beta-schardinger dextrin；The matrix is one in Macrogol 6000, poloxamer or stearic acid
Plant or several；The stabilizer is sodium dihydrogen phosphate and disodium hydrogen phosphate；The condensate liquid is atoleine.
Wherein, the matrix is preferably Macrogol 6000, poloxamer；Preferably, Macrogol 6000, poloxamer
Weight ratio be 1：1.
The Topiroxostat dripping pill of the present invention can be prepared as follows：
(1) it is medium with 80% ethanol, Topiroxostat and bag and material is dissolved in proportion, by resulting solution through filtering with microporous membrane
To clarifying, Topiroxostat inclusion compound is separated from mixture, Topiroxostat inclusion compound was crushed 100-200 mesh sieves by Bing；
(2) it is matrix and stabilizer ground and mixed is uniform, melting is heated on water-soluble, and mix；
(3) by step（1）The Topiroxostat inclusion compound prepared is added in step（2）In the fused mass prepared, mix, be poured into tiltedly
In liquid bath, 65-75 DEG C of keeping temperature 10 minutes；
(4) dripping pill is formed in the condensate liquid that above-mentioned decoction is instilled to 0-20 DEG C, adsorption condensing liquid is dried dripping pill, produced.
Topiroxostat dripping pill of the present invention has the advantages that：
(1) steady quality, increase drug dissolution and bioavilability, improve medicine stability；
(2) auxiliary material is common selected by, simple production process, and products obtained therefrom roundness is good, steady quality, is adapted to large-scale production.
Embodiment
The embodiment of the present invention is further described with reference to embodiment, but these embodiments are only examples
Property, any limitation is not constituted to the scope of the present invention.It will be understood by those skilled in the art that without departing from the present invention
Spirit and scope under the details and form of technical solution of the present invention can be modified or replaced, but these modification and replace
Each fall within protection scope of the present invention.
A kind of preparation method of Topiroxostat dripping pill, comprises the following steps：
(1) it is medium with 80% ethanol, Topiroxostat and bag and material is dissolved in proportion, by resulting solution through filtering with microporous membrane
To clarifying, Topiroxostat inclusion compound is separated from mixture, Topiroxostat inclusion compound was crushed 100-200 mesh sieves by Bing；
(2) it is matrix and stabilizer ground and mixed is uniform, melting is heated on water-soluble, and mix；
(3) by step（1）The Topiroxostat inclusion compound prepared is added in step（2）In the fused mass prepared, mix, be poured into tiltedly
In liquid bath, 65-75 DEG C of keeping temperature 10 minutes；
(4) dripping pill is formed in the condensate liquid that above-mentioned decoction is instilled to 0-20 DEG C, adsorption condensing liquid is dried dripping pill, produced.
The preparation of embodiment 1-6 Topiroxostat dripping pills
By the supplementary material in following prescriptions, method is prepared as described above, Topiroxostat dripping pill is made.Wherein, "/", which is represented, is not used.
The smooth rounding rate of Topiroxostat dripping pill obtained by the embodiment 1-6 of test example 1 and leach time limit measure
According to《Chinese Pharmacopoeia》The smooth rounding rate of the prepared dripping pill of method detection as defined in four general rules 0108 of version in 2015
With leach the time limit, measurement result is shown in Table 1.
Topiroxostat dripping pill investigation table obtained by the embodiment 1-6 of table 1
As it can be seen from table 1 the smooth rounding rate of the Topiroxostat dripping pill of embodiment 4 and leaching the time limit more preferably, illustrate the poly- second of use
Glycol 6000 and poloxamer are used as the Topiroxostat dripping pill excellent effect made by the matrix of coating.
The preparation of embodiment 7-11 Topiroxostat dripping pills
By the supplementary material in following prescriptions, method is prepared as described above, Topiroxostat dripping pill is made.
The smooth rounding rate of Topiroxostat dripping pill obtained by the embodiment 7-11 of test example 2 and leach time limit measure
Assay method is with test example 1, and measurement result is shown in Table 2.
Topiroxostat dripping pill investigation table obtained by the embodiment 7-11 of table 2
As known from Table 2, the smooth rounding rate of the Topiroxostat dripping pill of embodiment 9 and leach the time limit more preferably, illustrate when the poly- second two of matrix
The weight ratio of alcohol 6000 and poloxamer is 1:When 1, obtained drop of the Topiroxostat dripping pill relative to this non-special ratios
Ball has more excellent effect.
Claims (3)
1. a kind of Topiroxostat dripping pill, is made up of Topiroxostat inclusion compound, matrix and stabilizer, the inclusion compound includes support department
He and inclusion material, it is characterised in that remember by weight percentage, each component content is：
Topiroxostat 10%
Include material 15%
Matrix 75%
Stabilizer 1%
Appropriate condensate liquid.
2. according to the Topiroxostat dripping pill described in claim 1, it is characterised in that the inclusion material is beta-schardinger dextrin；The base
Matter is Macrogol 6000, poloxamer, and weight ratio is 1：1；The stabilizer is sodium dihydrogen phosphate and disodium hydrogen phosphate；Institute
Condensate liquid is stated for atoleine.
3. preparing the method for the Topiroxostat dripping pill described in claim 1, comprise the following steps：
(1) it is medium with 80% ethanol, Topiroxostat and inclusion material is dissolved in proportion, by resulting solution through filtering with microporous membrane
To clarifying, Topiroxostat inclusion compound is separated from mixture, Topiroxostat inclusion compound was crushed 100-200 mesh sieves by Bing；
(2) it is matrix and stabilizer ground and mixed is uniform, melting is heated on water-soluble, and mix；
(3) by step（1）The Topiroxostat inclusion compound prepared is added in step（2）In the fused mass prepared, mix, be poured into tiltedly
In liquid bath, 65-75 DEG C of keeping temperature 10 minutes；
(4) dripping pill is formed in the condensate liquid that above-mentioned decoction is instilled to 0-20 DEG C, adsorption condensing liquid is dried dripping pill, produced.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710351488.6A CN107157943B (en) | 2017-05-18 | 2017-05-18 | Topiroxostat preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710351488.6A CN107157943B (en) | 2017-05-18 | 2017-05-18 | Topiroxostat preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107157943A true CN107157943A (en) | 2017-09-15 |
| CN107157943B CN107157943B (en) | 2021-02-19 |
Family
ID=59815523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710351488.6A Active CN107157943B (en) | 2017-05-18 | 2017-05-18 | Topiroxostat preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107157943B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110898017A (en) * | 2019-12-11 | 2020-03-24 | 正大制药（青岛）有限公司 | Frovatriptan succinate dropping pill and preparation method thereof |
| CN110934836A (en) * | 2019-12-11 | 2020-03-31 | 正大制药（青岛）有限公司 | Topiroxostat dropping pill and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239046A (en) * | 2008-03-11 | 2008-08-13 | 刘全胜 | Epalrestat dropping pills and preparation thereof |
| CN101658520A (en) * | 2008-08-26 | 2010-03-03 | 天津泰普药品科技发展有限公司 | Medicinal composition for treating hyperuricemia |
| CN103083269A (en) * | 2013-02-19 | 2013-05-08 | 青岛正大海尔制药有限公司 | Dropping pills containing mannose ester and preparation method thereof |
| CN104352556A (en) * | 2014-11-13 | 2015-02-18 | 重庆泰通动物药业有限公司 | Radix sophorae flavescentis total alkaloids dropping pill |
| CN105030709A (en) * | 2015-07-29 | 2015-11-11 | 成都科创佳思科技有限公司 | Metroprolol succinate dropping pills and preparation method thereof |
-
2017
- 2017-05-18 CN CN201710351488.6A patent/CN107157943B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239046A (en) * | 2008-03-11 | 2008-08-13 | 刘全胜 | Epalrestat dropping pills and preparation thereof |
| CN101658520A (en) * | 2008-08-26 | 2010-03-03 | 天津泰普药品科技发展有限公司 | Medicinal composition for treating hyperuricemia |
| CN103083269A (en) * | 2013-02-19 | 2013-05-08 | 青岛正大海尔制药有限公司 | Dropping pills containing mannose ester and preparation method thereof |
| CN104352556A (en) * | 2014-11-13 | 2015-02-18 | 重庆泰通动物药业有限公司 | Radix sophorae flavescentis total alkaloids dropping pill |
| CN105030709A (en) * | 2015-07-29 | 2015-11-11 | 成都科创佳思科技有限公司 | Metroprolol succinate dropping pills and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110898017A (en) * | 2019-12-11 | 2020-03-24 | 正大制药（青岛）有限公司 | Frovatriptan succinate dropping pill and preparation method thereof |
| CN110934836A (en) * | 2019-12-11 | 2020-03-31 | 正大制药（青岛）有限公司 | Topiroxostat dropping pill and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107157943B (en) | 2021-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106667918A (en) | Ganaxolone formulations and methods for the making and use thereof | |
| JP2016539955A (en) | Drug composition, method for producing the same, and use | |
| CN103784411B (en) | A kind of erlotinid hydrochloride Pharmaceutical composition and preparation method thereof | |
| CN110037994A (en) | A kind of brufen quick-release and slow-release double-layer tablets and preparation method thereof | |
| CN107157943A (en) | A kind of Topiroxostat preparation and preparation method thereof | |
| CN103120652B (en) | Phloroglucin orally disintegrating tablet and preparation method thereof | |
| CN101204392A (en) | Self-emulsifying microemulsion daidzein oral liquid preparation composite and preparation method thereof | |
| CN110063944B (en) | Levamlodipine besylate atorvastatin calcium tablet and preparation method thereof | |
| CN101309692A (en) | Application of curbitacin or curbitacin combination in leucocyte increasing medicament preparation | |
| CN116942743A (en) | Preparation method of Ganmaoqing tablet and product thereof | |
| CN105636588A (en) | Formulations containing gamma secretase modulators | |
| CN100502850C (en) | Medicinal composition of total capsicine compounds and beta-cyclodextrin or derivative of beta-cyclodextrin | |
| CN114129528B (en) | Novel sildenafil citrate preparation with clinical advantages and preparation process and application thereof | |
| CN1919339B (en) | Cucurbitacin nano preparation comprising protein, preparation method and use thereof | |
| CN103284953B (en) | Bicyclol solid preparation and preparation method thereof | |
| CN111529500B (en) | Pharmaceutical composition for improving solubility of oryzanol and preparation method thereof | |
| CN101108224A (en) | Plants natural base extractive and formulated product and use thereof | |
| CN108379237A (en) | A kind of medicament microcapsule preparation for the treatment of of urinary tract infections and preparation method thereof | |
| CN116531326B (en) | Oral emulsion of apremilast and preparation method thereof | |
| CN116850248B (en) | Kekeping capsule and its preparation method | |
| CN103083269B (en) | Dropping pills containing mannose ester and preparation method thereof | |
| CN103127027B (en) | Polysaccharide sulphate dropping pill | |
| CN110934836A (en) | Topiroxostat dropping pill and preparation method thereof | |
| CN113599361B (en) | Ginkgo terpene lactone dripping pill and its preparing method | |
| CN107550874A (en) | A kind of Rupatadine fumarate tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 266000 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Applicant after: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd. Address before: 266000 3601 Tuen Jie Road, Qingdao economic and Technological Development Zone, Shandong Applicant before: Qingdao Zhengda Haier Pharmaceutical Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: No. 3601 Tuanjie Road, Qingdao Economic and Technological Development Zone, Shandong Province Patentee after: Qingdao Guoxin Pharmaceutical Co.,Ltd. Country or region after: China Address before: No. 3601 Tuanjie Road, Qingdao Economic and Technological Development Zone, Shandong Province Patentee before: CP PHARMACEUTICAL (QINGDAO) Co.,Ltd. Country or region before: China |